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SUMMARY 
Pancreatic cancer is one of the most aggressive and lethal forms of cancer, with high 
mortality and short survival. Chemotherapy using Gemcitabine is the most common treatment 
used but tumours frequently show resistance to the drug, necessitating the development of 
new and more potent therapy options. The use of replication-selective oncolytic adenoviruses 
constitutes a novel and promising way of combating cancer with proven efficacy and safety, 
as well as potentially synergistic effects when combined with chemotherapy. Previous work 
by Leitner et al (2009) has shown that combining Gemcitabine with an adenoviral mutant 
deleted in the anti-apoptotic E1B19K gene (Ad5Δ19K) increases the cytotoxic effect of the 
treatment in vitro and in vivo. Based on that work, an adenoviral mutant, Ad5ΔΔ, was created 
as a potential new candidate for treatment of pancreatic cancer. It has a deletion of the pRb-
binding E1ACR2 region in addition to the E1B19K deletion, abolishing its ability to induce 
S-phase and to prevent apoptosis. It is hypothesised that, due to the double deletions, the 
mutant will show increased selectivity to cancer cells, making it safer than its single deleted 
counterpart (Ad5Δ19K) but still retaining efficacy. Ad5ΔΔ has already showed promising 
results in pancreatic cancer cell line PT45 and normal immortalised cells. In this project, the 
cytotoxic and replicative ability of Ad5ΔΔ is tested on a wider range of pancreatic cancer 
cells as well as its capacity to sensitise pancreatic cancer cells to Gemcitabine and Irinotecan, 
drugs used in treatment of pancreatic cancer. The results show efficient replication of the 
viral mutant in all cell lines and moderate cytotoxicity of viral single treatment. An 
antagonistic effect was observed between viral and Gemcitabine treatment in cell lines 
insensitive to chemotherapy. However, cells that showed sensitivity to single treatment with 
drugs could be significantly sensitised by combining Ad5ΔΔ infection with chemotherapy.  
SAMMANFATTNING 
Bukspottkörtelcancer är en av de mest dödliga cancerformer som finns, mortaliteten är i 
princip hundraprocentig. Gemcitabine är förstahandsval i cellgiftsbehandlingen av 
sjukdomen. Tyvärr försvåras behandlingen ofta av resistensutveckling mot de 
kemoterapeutiska preparat som finns att tillgå. Det dåliga svaret på befintlig terapi gör det 
nödvändigt att utveckla nya och mer framgångsrika behandlingsalternativ. Selektivt 
replikerande onkolytiska adenovirus utgör en ny och lovande plattform för framtida 
cancerbehandling, oftast i kombination med befintlig cytostatikaterapi. Tidigare försök av 
Leitner et al (2009) har visat att man kan uppnå ökad cytotoxicitet hos cancerceller såväl in 
vitro som in vivo genom att kombinera Gemcitabine-behandling med en adenovirusmutant 
Ad5Δ19K. Ad5Δ19K besitter en deletion i den anti-apoptotiska genen E1B19K och saknar 
därmed förmågan att motverka programmerad celldöd. Baserat på dessa fynd har en ny 
mutant, Ad5ΔΔ, skapats med förhoppning om att denna kan bli en ny läkemedelskandidat 
inom behandling mot bukspottkörtelcancer. Utöver samma E1B19k-deletion som Ad5Δ19K, 
har Ad5ΔΔ även en deletion i den pRb-bindande E1ACR2-regionen. Den senare omöjliggör 
för viruset att framkalla övergång från G1- till S-fas i värdcellen. Förhoppningen med Ad5ΔΔ 
är att det genom sina dubbla deletioner ska vara ett säkrare virus att använda samtidigt som 
det visar effektiv cytotoxicitet i cancerceller. Viruset har redan visat lovande resultat i 
cancercellinjen PT45 samt i normala, immortaliserade cellinjer. I detta projekt utvärderas 
Ad5ΔΔs replikativa och cytotoxiska egenskaper på en större panel bukspottkörtelcancerceller 
samt dess förmåga att sensitisera cancerceller för Gemcitabine och Irinotecan, cytostatika 
som används i behandlingen av bukspottkörtelcancer. Resultaten visar effektiv 
virusreplikation i alla cellinjer samt måttlig cytotoxicitet. I cellinjer som är okänsliga för 
cytotstatika sågs antagonism mellan virus och läkemedelsbehandling, medan cellinjer som är 
känsliga för cellgifter kunde sensitiseras genom samtidig viral behandling.  
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INTRODUCTION 
Viral gene therapy against cancer 
Gene therapy can be defined as “a technique for correcting defective genes responsible for 
disease development” (Oak Ridge National Laboratory, 2009). Its aim is to restore the normal 
state of the target cell by expressing an inserted gene and producing a functional gene 
product. Cancer is the disease most commonly targeted by gene therapy in clinical trials; over 
60% of all gene therapy trials globally are conducted to test a new treatment against cancer 
(Fig. 1). However, the approach in cancer gene therapy differs from gene therapy used 
against other genetic diseases; instead of restoring the normal state of the cell, the aim is to 
kill it. In the majority of clinical cancer trials this is achieved by using viruses as vectors (Fig. 
2).  
 
Fig. 1: Gene therapy in clinical 
trials. 
http://www.wiley.co.uk/genmed/clinical/ 
(2009-05-08) 
 
 
 
Viruses have evolved to efficiently transfer their genome into host cells and enable 
replication of viral genes within the cell (Walther and Stein, 2000). It is this ability that 
makes them suitable as delivery systems for therapeutic genes. Both RNA as well as DNA 
viruses can be used as vectors (Mancheño-Corvo and Martín-Duque, 2006) but the 
employment of DNA viruses is more wide spread. The most frequently used viral vectors 
derive from retroviruses, adenoviruses, adeno-associated viruses (AAV), poxviruses and 
herpesviruses, accounting for over 60% of the vectors used in clinical trials worldwide (Fig. 
2). 
 
 
Fig. 2: Vectors used in gene therapy. 
http://www.wiley.co.uk/genmed/clinical/ 
(2009-05-08) 
 
 
There are basically three different methods by which viral vectors can target cancer cells 
(Reid et al, 2002, Ahn et al, 2009):  
1. Gene delivery by non-replicating viruses 
2. Oncolysis through replicating viruses (oncolytic virotherapy)  
3. Combination of replication-induced oncolysis and expression of therapeutic genes  
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Oncolytic virotherapy 
Oncolytic virotherapy means using the virus as a form of therapy causing oncolysis (lysing of 
tumour cells). Upon infection, the virus replicates within the cancer cell, giving rise to 
progeny viral particles that at the end of the viral life cycle burst the host cell, thereby killing 
it. Oncolytic viruses are viruses with either an inherent ability to infect and kill cancer cells or 
viruses that have been genetically engineered to do so, so called viral mutants (Parato et al, 
2005).  
In comparison to conventional cancer therapies, there are some noteworthy benefits with 
oncolytic vectors (Parato et al, 2005). Through recombinant DNA technology, they can be 
genetically engineered for optimal effects in the target cells. Genes can be deleted or added, 
increasing selectivity and potency. Viruses are naturally immune-stimulatory agents and can 
induce a host immune response against cancer cells, promoting tumour-specific inflammation 
(Väha-Koskela et al, 2007). Through the addition of immunogenic genes into the viral 
genome the immune response against the tumour can be potentiated. Their ability to self-
replicate within the cancer cell and spread to neighbouring cells enables treatment to be self-
perpetuating.  It also means that for the virus to be safe, its replication has to be restricted to 
tumour cells only. There are many ways by which viral selectivity for cancer cells can be 
achieved (Parato et al, 2005). The two main approaches used today are tumour/tissue specific 
promoter regulated transcription of viral genes and mutational complementation (Wang et al, 
2005). Viral uptake can be increased by targeting tumour specific antigens (Parato et al, 
2005) and cancer cell killing can be further optimised through the combination of oncolysis 
with the delivery of toxic genes (Ahn et al, 2009). 
 
Adenoviruses 
Adenoviruses are the most commonly used oncolytic viral vectors (Fig. 2). They were first 
isolated and characterised in the 1950s (Shenk, 2001). The virus was isolated from human 
adenoid tissue (pharyngeal tonsils) from patients with respiratory disease. It is that original 
tissue that has given rise to the name of the virus. Over 51 serotypes of human adenoviruses 
have been identified (Russel, 2009). The serotypes are further divided into 6 subgroups, A-F, 
based on hemagglutination ability (Shenk, 2001). Adenoviruses used for gene therapy are 
mainly derived from subgroup C (Aghi and Martuza, 2005). Viral tropism differs with 
serotype but, in general, human adenoviruses show a tropism for epithelium and cause mainly 
respiratory disease (Shenk, 2001). Infection is normally subclinical but can be severe in 
immunosuppressed individuals (Quinn et al, 2002).  
Adenovirus structure and genome organisation 
Adenovirus is a non-enveloped, double-stranded DNA 
virus with a linear genome contained in an icosahedral 
protein shell called the viral capsid (Shenk, 2001). 
Particles range in size from 70nm to 100nm. The 
capsid is composed of structural subunits, including 
the hexon and penton capsomeres (Fig. 3).  
Fig. 3: Structure of the adenovirus. 
http://nobelprize.org/nobel_prizes/medicine/laureates/199
3/illpres/big-adenovirus-v3.gif (2009-06-02) 
4 
 
All human adenoviruses have the same genome organisation, which means that the gene 
location along the genome does not differ between serotypes (Shenk, 2001). The viral 
genome is divided into early (E) and late (L) transcription units, with multiple gene products 
synthesised from each unit (Fig. 4).  
 
Fig. 4: Schematic representation of the adenoviral genome organisation.  
Early proteins are labelled E and late proteins L.  MLP Major Late Promoter (Ferreira et al, 2005). 
 
Adenovirus lifecycle 
The adenoviral life cycle can roughly be divided into three phases: 
1) Attachment and entry 
2) Viral gene transcription and replication 
3) Virion assembly and release from the cell 
 
The entire cycle lasts about 24 hours (Shenk, 2001).  Most gene therapy studies are based on 
the closely related serotypes Ad2 and Ad5 of subgroup C (Aghi and Martuza, 2005).  
 
Attachment and entry 
The virus first attaches to the cell through interactions between the viral fiber protein and cell 
surface structures. First, the fibre knob of the viral capsule binds to the cell surface protein 
coxsackie and adenovirus receptor (CAR) followed by attachment of the viral pentonbase to 
cellular integrins αVβ1 and αVβ5 (Shenk, 2001). After endosome mediated internalisation, 
the virus migrates through the cytoplasm, sheds its protein shell and enters the nucleus 
through membrane pores. Once inside the nucleus, expression of early viral genes is initiated.  
Viral gene transcription and replication 
The first gene to be expressed after viral infection is E1A, whose main function it is to push 
the cell into S-phase, creating an environment which is favourable for replication of the viral 
genome (Shenk, 2001). E1A encodes two major proteins, 13s and 12s, whose conserved 
regions (CR) bind to and influence cellular transcription factors and gene regulatory proteins. 
This in turn leads to increased transcriptional activity in the cell and subsequent expression of 
viral genes necessary for the survival and replication of the virus within the host. The virus 
utilises mainly two pathways to provoke the quiescent cell into unscheduled cell cycle 
progression: inactivation of retinoblastoma tumour suppressor protein (pRb) and blocking of 
E1A binding protein p300 (EP300) in complex with CREB-binding protein (CBP). pRb 
normally binds to and inactivates the transcription factor E2F, preventing the transcription of 
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genes that promote progression from G1- into S-phase. The CR2 domain of the E1A proteins 
binds to and inactivates pRb which releases E2F, allowing cell cycle progression including 
replication of both cellular as well as viral DNA by the host replication machinery. p300 and 
CBP serve as co-activators for a number of transcription factors, including tumour suppressor 
p53. By inhibiting their activity through the CR1 domain of E1A, the virus can manipulate 
the expression and function of host genes.  
Five to eight hours after infection, intranuclear viral DNA replication commences and 
continues until the cell dies (Shenk, 2001). The E2 genes encode proteins needed for viral 
DNA synthesis. Some cellular proteins, such as nuclear factors (NF) I, II and III, are also 
used in the viral replication process.  Once viral DNA replication starts, late viral genes 
encoding structural proteins are expressed, enabling assembly of virions. The late genes are 
transcribed as a single, large primary mRNA molecule and turned into multiple, smaller 
transcripts (L1-L5) through splicing. The major late promoter controls the expression of the 
late viral proteins and is activated at the onset of replication.  
Numerous defence mechanisms have been developed by the host to counteract the 
propagation of virus within the cell. The virus, in turn, has developed ways to avoid these 
antiviral defence mechanisms. The main aim of the cellular defence is to induce programmed 
cell death of infected cells, elicited through two major pathways: the intrinsic and the 
extrinsic apoptotic pathways. Unscheduled progress into S-phase induced by the adenovirus, 
elicits up-regulation of the tumour suppressor protein p53. p53 in turn activates effector 
proteins of the apoptosis pathway (Bax, PUMA) which promote downstream activation of a 
caspase cascade leading ultimately to cell death and disintegration. To prevent this from 
happening, the virus encodes two proteins, E1B55K and E4orf6, which are transcribed 
shortly after E1A expression. E1B55K and E4orf6 together bind to p53 and promote the 
proteosomal degradation of the tumour suppressor, preventing premature cell and 
subsequently viral death. Adenoviral infection can also induce a response through the 
extrinsic apoptotic pathway, involving mainly the cytokine TNFα and signalling through the 
death receptor Fas (Liu et al, 2005). Fas ligands, like TNFα, bind to the Fas receptor and 
activate caspases via Fas-associated protein with death domain, FADD. To counteract the 
action of TNFα-induced cell death, adenoviruses have developed the E1B19K protein; a 
functional homologue to the cellular anti-apoptotic protein Bcl2 (B-Cell Lymphoma 2). 
E1B19K binds to and blocks downstream effectors of apoptosis, thereby preventing 
premature cell death.  
Virion assembly and release from cell  
Viral transcripts are initially translated together with cellular equivalents (Shenk, 2001). As 
the infection progresses, the transport of cellular mRNAs to the cytoplasm is blocked by viral 
E1B and E4 proteins. This promotes the accumulation of late viral transcripts in the 
cytoplasm.  In the cytosol, the viral mRNAs are translated into either structural proteins like 
components of the viral capsid or auxiliary proteins for virion assembly. A special packing 
sequence in the viral genome mediates DNA-capsid recognition and initiates the assembly of 
the capsid.  Once an intact viral shell has been assembled, the viral DNA is added. Through 
processing of the capsid components by the L3 protein, the formed virion is rendered 
infectious. Two viral systems are responsible for killing the host cell. Firstly, L3 promotes 
breakdown of the cytoskeleton, enabling release of the viral particles by lysing the cell. 
Secondly, an E3-encoded protein adenovirus death protein (ADP) accumulates in the 
cytoplasm during the later stages of infection. The mechanism by which cell death is induced 
by ADP is still not entirely understood. 
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Conditionally replicating oncolytic adenoviruses 
Adenoviruses are suitable as oncolytic viral vectors for a number of reasons. The genes 
responsible for infection, replication and pathogenesis are well known and the viral genome 
is easily manipulated (Shenk, 2001). In contrast to retroviruses, adenoviral genes are not 
incorporated into the host genome, abolishing the risk of insertional mutagenesis. 
Adenoviruses can infect both proliferating and non-growing cells (Horwitz, 2001), allowing 
the use of oncolytic mutants against slow growing tumours like prostate cancer. Also, viral 
replication and cellular carcinogenesis require inactivation of the same defence 
mechanisms/tumour suppressor pathways, enabling the selective targeting of cancer cells 
through genetic engineering of the virus (O‟Shea, 2005).  
Use of engineered adenoviral vectors have shown promising results in clinical trials, 
producing few and mild side-effects (Reid et al, 2002) with proven selectivity for  cancer 
cells (Liu et al, 2004; Liu et al, 2005; Leitner et al, 2009). Tumour-selectivity of 
adenoviruses has mainly been achieved through mutational complementation or 
tumour/tissue specific promoter regulation of viral replication (Liu et al, 2005).  
Regulation of viral transcription by tumour/tissue specific promoters 
By placing viral genes essential for replication, for example E1A, under the control of 
promoters or enhancer elements that are up-regulated in cancer cells, the replication and 
subsequently oncolytic activity of the virus can be restricted to tumour cells (Ahn et al, 
2009). This approach has been widely used for the targeting of prostate cancer, placing viral 
replication under the control of androgen receptor (AR) response elements. AR is a hormone 
dependent transcription factor that is frequently mutated and over-expressed in late stage 
prostate cancers.   
Mutational complementation 
Mutational complementation takes advantage of the “evolutionary convergence between the 
processes of carcinogenesis and adenoviral replication” (Liu et al, 2005). Both 
tumourigenesis and viral replication within a host depend on uncoupling cellular growth and 
proliferation processes from the safety and control mechanisms governed by multi-purpose 
tumour suppressor genes. For instance, many cancer cells have mutations blocking apoptotic 
pathways, like loss-of-function mutations of p53 (O‟Shea, 2005) or abnormal and non-
functional TNF-α signalling (Liu et al, 2005). Viruses on the other hand, have developed 
proteins like E1B55K/E4orf6 and E1B19K to block the induction of apoptosis in infected 
cells (Shenk, 2001). By deleting anti-apoptotic genes of a viral mutant, its replication can be 
restricted to cells in which cell death pathways are already non-functional, i.e. cancer cells. 
The virus would still be able to infect a normal cell, but as the apoptotic pathways are intact, 
the cell will undergo virally induced apoptosis and the infection will not spread (Fig. 5).  
 
Fig. 5: Restriction of viral 
replication to cancer cells 
through selective 
replication. 
Courtesy of Dr. Gunnel 
Halldén 
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Mutation of tumour suppressor p53 is the most commonly found genetic alteration in cancer 
cells. Several adenoviral mutants targeting this particular feature have been developed. One 
of which is ONYX-015 (dl-1520), the first adenoviral mutant used in clinical trials, designed 
to replicate selectively in p53-deficient cells (Ganly et al, 2000). It is deleted in the E1B55K 
region, making it unable to mediate destruction of p53 and thereby avoid p53-induced 
apoptosis. ONYX-015 has given rise to the first adenoviral mutant licensed for cancer 
therapy, Shanghai Sunway Biotech‟s H101, which is used in China to treat patients with head 
and neck cancer (Garber, 2006). Despite being proven safe and cancer cell specific in 
numerous trials, the efficacy of ONYX-015 as a single treatment is poor.  However, the 
cytotoxic activity of the mutant can be markedly increased through combination with 
chemotherapy (Khuri et al, 2000). 
Another aberration commonly found in cancer cells is inactivation of pRb and subsequently a 
defective G1-S-phase checkpoint. This main regulator of cell cycle progression is also 
targeted by adenoviral mutants, one of which is dl922-947 (Heise et al, 200). dl922-947 is 
deleted in the pRb binding E1ACR2 domain, a mutation that abolishes the viral ability to 
inactive pRb and push the cell into S-phase. Due to this loss of function, viral replication and 
survival is restricted to cancer cells with non-functional pRb pathways. dl922-947 shows 
good cytotoxic potential, efficiently killing a broad range of cancer cells, but is less safe than 
previous mutants like ONYX-015. The virus is namely to some extent capable to replicate in 
normal but proliferating cells because these, like cancer cells, have inactivated cell cycle 
checkpoints.  
So whereas ONYX-015 shows promising safety properties but inefficient cytotoxic potential, 
dl922-947 possesses good cell killing qualities but is lacking in safety. One major problem 
with conditionally replicating viruses is that “gene deletions conferring selectivity also 
frequently result in reduced potency of the virus in tumours” (Heise et al, 2000). The focus in 
cancer gene therapy today therefore lies in producing a mutant that is able to kill cancer cells 
efficiently but unable to replicate in normal cells, both quiescent and proliferating.  
 
Pancreatic cancer 
Pancreatic cancer is the 11
th
 most common form of cancer in the UK, with 6500-7000 new 
cases each year (CRUK CancerStats, 2006). The number of people affected does not differ 
between men and women but the incidence rate is slightly higher in men, especially with 
increased age. With roughly 7000 deaths a year in the UK, pancreatic cancer is the sixth most 
common cause of cancer related death. Symptoms associated with pancreatic cancer are 
vague and slow in onset, leading to patients often being diagnosed at a late stage. In the US, 
the average age at diagnosis is 72 (American Cancer Society, 2008). Usually time between 
diagnosis and death never reaches more than six months; the five year survival rate is only 2-
3% in the UK and it has not improved in the last 40 years (CRUK CancerStats, 2006). 
The main risk factors of pancreatic cancer are old age, smoking, obesity, diabetes mellitus 
type II (insulin-independent diabetes) and hereditary chronic pancreatitis (CRUK 
CancerStats, 2006). Smoking is the only established preventable factor.  Other factors that 
influence the risk of developing pancreatic cancer include exercise, diet, exposure to 
chemicals and radiation and certain genetic disorders. 
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The absolute majority of pancreatic tumours originate from the exocrine pancreas, 95% of 
these are malignant adenocarcinomas (CRUK CancerStats, 2006). Mutations of the proto-
oncogene k-Ras, tumour suppressor gene p53 and p16 are the most frequently observed 
genetic alterations in ductal adenocarcinomas (Moore et al, 2001).  
The treatment options for pancreatic cancer are the same as for most forms of cancer: surgery 
(curative or palliative), radiotherapy, chemotherapy or combinations of two or more of the 
alternatives. At the time of diagnosis most cancers will have spread, making surgical 
resection impossible (Mulvihill et al, 2001). The first line of treatment after surgery is the 
chemotherapeutic drug Gemcitabine (Gemzar®). Gemcitabine (2‟, 2‟-difluoro 2‟-
deoxycytidine, dFdC) is a cytidine analogue which is incorporated into the cellular genome, 
leading to premature DNA chain termination, cell cycle arrest and subsequent apoptosis 
(Mini et al, 2006).  Despite being the standard chemotherapy for pancreatic cancer, 
Gemcitabine only prolongs the average patient survival by about 6 months (O‟Reilly, 2009). 
Other drugs used in pancreatic cancer treatment, mostly in combination with Gemcitabine, 
include cisplatin, irinotecan (Campto®), paclitaxel (Taxol®) and docetaxel (Taxotere®), 
(American Cancer Society, 2008). Irinotecan (camptothecin) is a topoisomerase I inhibitor 
and functions like Gemcitabine as a DNA damaging agent. Topoisomerase I is an ubiquitous 
and essential enzyme that is responsible for the uncoiling of the nucleotide strands during 
DNA replication (Rothenberg, 1997).  During uncoiling, single strand breaks are created in 
the DNA, enabling unwinding of the helix without torsional stress. Once the strands are 
uncoiled, the breaks are religated, allowing replication to occur. This process is catalysed by 
topoisomerase I. Camptothecin binds to topoisomerase I and blocks the religation step, 
leaving the DNA strand cleaved, which in turn brings the replication to a halt.   
Despite availability of advanced medical and surgical treatment the prognosis of pancreatic 
cancer remains very poor. One important explanation for this is the fact that most pancreatic 
tumours are resistant or insensitive to available chemotherapeutic drugs (Mulvihill et al, 
2001). The mechanisms behind drug resistance in pancreatic cancer are not fully understood 
but a partial explanation is the poor blood perfusion of pancreatic tumours creating a hypoxic 
environment within the mass. The unsatisfying results of current available treatment options 
necessitate the development of novel therapies such as oncolytic virotherapy. 
Oncolytic virotherapy against pancreatic cancer 
Leitner et al (2009) developed an E1B19K deleted Ad5 mutant (Ad5∆19K) that in 
combination with Gemcitabine showed enhanced cytotoxicity. The virus was tested on the 
pancreatic cancer cell lines Suit-2 and PT45 and both cell lines showed significant 
sensitisation to Gemcitabine induced cell death in response to the combination treatment. 
Promising results were also observed in vivo using PT45 xenografts in athymic mice, which 
showed inhibition of tumour growth and prolonged survival. One interesting finding was that 
the synergistic effect on cell death was caused by enhancement of Gemcitabine-induced 
apoptosis, possibly explained by the pro-apoptotic functions of the E1A protein that could not 
be prevented in the absence of E1B19K gene expression. To further improve on viral 
potency, selectivity and to elucidate the mechanisms involved in the synergy, another viral 
mutant was constructed by the Viral Gene Therapy (VGT) group at the Centre for Molecular 
Oncology and Imaging at Barts and the London School of Medicine and Dentistry. This 
mutant, Ad5∆E1ACR2∆E1B19K (Ad5ΔΔ), is deleted in both the E1B19K region and the 
pRb binding CR2 domain of the E1A gene (Öberg et al, manuscript in preparation). It is 
hypothesised that the virus, through the double deletion, will prove to be safer and more 
selective than previous mutants because of the inability to bind pRb and induce S-phase in 
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normal cells.  It is also hypothesised that through the defective E1A protein, the induction of 
apoptosis might be reduced or delayed, potentially resulting in higher viral replication in 
tumour cells even in the absence of the anti-apoptotic E1B19K protein. Dr. Cherubini of the 
VGT group has been testing the Ad5ΔΔ mutant in combination with Gemcitabine in PT45 
cells and observed sensitisation to the drug (Dr. Cherubini, personal communication).  She 
has also conducted replication studies with Ad5ΔΔ in primary cells, confirming the 
hypothesis that this mutant is unable to replicate in normal cells (unpublished data). The 
primary cells used in these studies were normal human bronchial epithelial (NHBE) cells (Dr. 
Cherubini, personal communication). 
 
Project aims 
The aim of this project was to screen Ad5ΔΔ in three different pancreatic cancer cell lines, 
evaluating replication and cytotoxicity. There were three main questions to be answered in 
the course of this work:  
 Does Ad5ΔΔ replicate efficiently in pancreatic cancer cells?  
 Does Ad5ΔΔ sensitise pancreatic cancer cells to chemotherapy? 
 Does Ad5ΔΔ retain the ability to selectively kill cancer cells, as seen in the single 
deleted counterpart Ad5Δ19K?  
 
The cell lines chosen were PANC-1, Suit-2 and BxPc-3, all pancreatic cancer cells lines with 
different origin and/or mutations. PANC-1 and BxPc-3 cells derive from primary 
adenocarcinomas, whereas Suit-2 cells originate from liver metastases. The majority of 
pancreatic cancer cells are ductal adenocarcinomas with mutations of the oncogene kRas 
(Moore et al, 2001). Most of these cells are kRas dependent, i.e. if the kRas pathway is 
successfully blocked, the cells will die. However, within the population of kRas mutated 
pancreatic cancer cells, there are cells which are independent of the activity of the kRas 
oncogene (Singh et al, 2009). To reflect the diversity in mutations found in pancreatic cancer 
cells, we chose two cell lines that are kRas mutated (PANC-1 and Suit-2), one kRas 
independent (PANC-1) and one kRas dependent cell type (Suit-2). BxPc-3 cells carry the 
kRas wild type. Apart from mutations in kRas, all cell lines used in the screening have 
mutations in tumour suppressor genes p53 and p16, another common feature of most 
pancreatic cancer cells (Moore et al, 2001).  
If Ad5ΔΔ can show ability to efficiently replicate in pancreatic cancer cells and sensitise cells 
to chemotherapy in both in vitro and in vivo studies, the virus can be considered as a 
candidate for clinical trials. In the screening, Ad5ΔΔ was compared to three other 
adenoviruses: a wild type (wt) control Ad5tg and the single-deleted mutants Ad5Δ19K and 
ONYX-015 (dl1520). In some replication studies, a replication-defective adenovirus Ad5GFP 
was used as a negative control. The level of replication and subsequent cell killing was 
considered efficient if it approximated or exceeded that of the wt control. ONYX-015 was 
included in the study as it has been so frequently used in oncolytic research and offers a great 
deal of reference data. The drugs used to evaluate the sensitisation potential of the viral 
mutants were Gemcitabine (Gemzar®) and Irinotecan (Compto®), both currently used in the 
treatment of pancreatic cancer.   
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MATERIAL AND METHODS 
Cells and cell culture 
The cell lines used in the screening are PANC-1, Suit-2 and BxPc-3. These were obtained 
from the American Type Culture Collection (ATCC; VA, USA) and Cancer Research UK 
Cell Services (Clare Hall, CRUK, London). JH293 cells used for TCID50 assays were also 
provided from the Cancer Research UK Cell Services.  
Cells were grown in Dulbecco‟s Modified Eagle Medium (DMEM) with high 4.5 g/L glucose 
(PAA Laboratories GmbH, Pasching, Austria) containing L-glutamine, sodium pyruvate, and 
supplemented with 10% foetal calf serum (FCS) (PAA) and 1% penicillin/streptomycin (100 
x) (PAA). The cells were passaged every 3-4 days using phosphate buffered saline (PBS) to 
wash the cells and trypsin (PAA) to detach the monolayer. The cells were incubated in a 
humidified atmosphere with 5% CO2 and a temperature of 37°C. All reagents needed for cell 
culture were supplied by Cancer Research UK Cell Services. 
 
Viruses and chemotherapeutic drugs 
The viruses used in the project were: Ad5tg (wild type adenovirus type 5), Ad5Δ19K (Adtg 
deleted in the E1B19K-gene), Ad5ΔΔ (Adtg deleted in the E1ACR2-region and the E1B19K-
gene) and ONYX-015 (dl1520; deleted in the E1B55K-gene) and Ad5GFP (non-replicating 
deleted in E1-genes). All viruses derive from the Ad5 serotype C and are replication-
competent with the exception of Ad5GFP. Ad5tg is generated from the Ad5 plasmid 
pTG3602 containing the Ad5 wild type genome (Leitner et al, 2009; Öberg et al, manuscript 
in preparation). All mutants were generated by homologous recombination of the pTG3602 
plasmid and plasmids containing the various deletions. Ad5GFP is a non-replicating virus 
deleted in E1 which has been replaced by CMV-GFP cassette. All viruses were constructed 
for in house use by the Viral Gene Therapy Group at the Centre for Molecular Oncology and 
Imaging at QMUL.  
The drugs used in the cytotoxicity assays were Gemcitabine HCl (Gemzar®, Eli Lilly, 
Basingstoke, UK) and Irinotecan (Compto®, Pfizer, Sandwich, Kent, UK). Gemcitabine was 
dissolved in PBS and stored at -20°C at a concentration of 100mM. Irinotecan was bought 
already in solution at a concentration of 34mM and kept at room temperature.  
 
MTS assays – cytotoxicity of chemotherapeutics and virus 
The sensitivity of the cell lines to Gemcitabine, Irinotecan, viruses as well as combination 
treatments was determined by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium) viability assays. Cells were 
seeded in DMEM media with 10% FCS on sterile 96 well plates at a cell density of 5000 
cells/well in 100µl media. One row of wells contained only media and was used as a blank 
for background absorbance. The following day the media was replaced by 2% DMEM and 
cells were infected or treated with serial dilutions of virus and drug respectively, in a final 
volume of 100µl. Each infection and drug treatment was done in triplicate wells. One row of 
cells on each plate was left untreated and used as a control. In combination treatment assays, 
the controls were cells exposed only to the drug but not virus.  
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The serial dilutions of drugs and virus were done on a separate 96 well plate. Viruses were 
diluted 5-fold and drugs 3-fold. The starting dose, the multiplicity of infection (MOI), of each 
virus was 1x10
5
 ppc. For the drug treatment, the equivalent row of wells contained 
concentrations of 40µM and 1mM for Gemcitabine and Irinotecan respectively. The MOI as 
well as drug concentrations were established in previous work in the pancreatic cancer cell 
lines PT45 and Suit-2 (Dr. Cherubini, personal communication). In cases where resistance to 
the drug was observed in a cell line, the drug concentration was increased to a maximum of 
400µM for Gemcitabine and 3.4mM for Irinotecan. When combination treatments were 
performed, 2% media with the calculated drug concentration was prepared separately and 
then added to the cells (90µl/well). Following this, serial dilutions of virus were added to the 
well in a volume of 10µl, keeping the total volume per well to 100µl throughout the assay.   
Three days after infection, the plates were read using the MTS reagent according to the 
manufacturer‟s instructions (Promega, Madison, WI, USA). In live, metabolically active 
cells, the tetrazolium salt MTS is converted to a soluble formazan product by mitochondrial 
dehydrogenase. The product absorbs light at 490nm and its synthesis can therefore be 
quantified by reading the plates in an ELISA microplate reader (Opsys MR, Dynex 
Technologies) at a wavelength of 490nm. The reaction product is directly proportional to the 
amount of viable cells on the plate. From the number of live cells, a measurement of the 
amount of cell death in each well could then be calculated. The absorbance values for treated 
or infected wells were corrected against the corresponding blank wells containing only media 
(background) and compared to the untreated/uninfected control wells. The amount of cell 
death for each serial dilution step was calculated according to the following formula: 
100 - [((average sample - average background)/average control - average background) * 100]  
The results of each triplicate experiment were averaged and expressed as percentages of cell 
death in comparison to the untreated controls. In combination treatments the controls used 
were cells treated with drug alone. The data analysis was performed using the GraphPad 
Prism graphics software and dose response curves were generated for each agent alone and as 
well as combination of virus and drugs. This generated sigmoid curves which enabled the 
determination of the effective drug and/or virus concentrations killing 50% (EC50 values) of 
cells. Examples of viral dose response curves in PANC-1 cells and drug dose response curves 
in Suit-2 cells can be seen in Fig. 6. It was noted that 100% cell death was never achieved 
with Gemcitabine after only three days of incubation and the EC50 values for single treatment 
with Gemcitabine were therefore extrapolated from available data points; the maximum 
achieved cell death was set to 100%, the minimum to 0% and value in between the set 
constraints was used as the EC50 value.  
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Fig. 6: Dose response curves to serial dilutions of virus (A) and drug (B) in PANC -1 
and Suit-2 cells respectively.  
Arrows indicate EC50 values of each individual treatment. Each infection and treatment was done in triplicates 
and the results averaged ± SD 
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Viral replication assays – TCID50 and quantitative PCR 
Viral replication and genome amplification in the cell lines was measured using a limiting 
dilution assay (TCID50; tissue culture infective dose at 50%) and quantitative polymerase 
chain reaction (qPCR) respectively. TCID50 measures the production of a virus in cells by 
quantifying the intact, infective viral particles released from and present in the infected cells. 
The results are determined as plaque forming units (PFU) per cell, a value that is calculated 
based on the cytopathic effect of the virions produced in the titre cell line (JH293 cells).  In 
contrast to the biological titration of a TCID50 assay, qPCR constitutes a physical method to 
estimate viral genome amplification. It quantifies the intracellular content of viral DNA by 
amplifying samples extracted from infected cells.  
Infection 
In the viral burst assay, samples for TCID50 assays and qPCR were created simultaneously by 
infecting pancreatic cancer cells and harvesting them at three given time points. From these 
cell samples, intact viral particles were extracted for further infection of JH293 cells in the 
TCID50 assay. From the qPCR samples, viral DNA was extracted and quantified.   
Pancreatic cancer cells were seeded in 10% DMEM in 6 well-plates at a cell density of 
100 000 cells/well for Suit-2 cells and 200 000 cells/well for PANC-1 and BxPc-3 cells. The 
total volume of each well was 2.0ml. After overnight incubation, the cells of one well were 
detached and counted. Based on this cell count, a virus dose correlating to an MOI of 100 ppc 
was calculated and cells infected accordingly. This value of 100 ppc was established in 
previous studies (Dr. Cherubini, personal communication). Viruses used for burst assays were 
Ad5tg and Ad5ΔΔ for TCID50 samples and Ad5tg, Ad5ΔΔ and Ad5GFP for qPCR samples. 
All infections were done in duplicates. The cells were infected in serum-free medium 
1.0ml/well for two hours after which the medium was removed and replaced with fresh 10% 
DMEM at a volume of 2.0ml/well. Cells were harvested at three time points after infection, 
24 hrs, 48 hrs and 72 hrs. Both cells and media were collected for the TCID50 assays (cells 
were scraped off the plates). Harvesting of qPCR samples was done by discarding the culture 
media and detaching the cells with trypsin. After inactivation of trypsin through addition of 
fresh DMEM, cells were centrifugated (5 min at 1500 rpm) and the pellet re-suspended in 
200μl PBS. TCID50 samples were stored at -80ºC and qPCR samples at -20ºC. 
TCID50 
JH293 cells, a subclone of the human embryonic kidney (HEK) cells, were seeded on sterile 
96 well plates at a cell density of 10 000 cells/well in a total volume of 200µl/well 10% 
DMEM. The following day burst assay samples were freeze-thawed with liquid nitrogen 
three times in order to break the cells and release intracellular viral particles. After 
centrifugation (5 min at 1500 rpm) samples were diluted 1:1000 and 20µl of the diluted 
solution was added to the top row of duplicate plates. The viral samples were serially diluted 
across the plates to a final dilution of 1:10
9
. The last row of cells on each plate was left 
uninfected and used as control. Three plates were infected with a control adenovirus (Ad5) 
which was used as to verify the accuracy of the assay. After 10 days of incubation at 37°C the 
plates were inspected and any sign of virally induced cytopathic effect (CPE) registered. 
Based on the CPE the titre of each burst assay sample was calculated using the Kärber 
formula (Kärber, 1931).  
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Quantitative PCR 
Burst assay samples for qPCR were produced simultaneously as samples for TCID50, using 
the non-replicating virus Ad5GFP in addition to Ad5tg and Ad5ΔΔ. Ad5GFP functioned as a 
negative control of replication. DNA was extracted from the samples according to QIAamp® 
DNA Mini and Blood Mini Handbook Spin protocol for Blood and Body Fluids 
(QIAGEN®). qPCR (7500 Real Time PCR System; Applied Biosystems) was done with the 
Power SYBR Green Master Mix (Applied Biosystems) and analysed by the System SDS 
software. Each individual sample was amplified in triplicates for each primer used: GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase), a cellular protein whose expression functions 
as a standard for cellular DNA quantity, and hexon, a viral structural protein, used as a 
measure of viral DNA production. All triplicate values were averaged and the viral DNA 
results normalised against the cellular DNA values.  Cycle threshold (Ct) values were 
exported into EXCEL worksheets for analysis and relative quantification was made using the 
2
-ΔΔCt 
method (Tichopad et al, 2003). Relative quantification of DNA content meant that the 
qPCR value of each sample and timepoint was compared to the Ad5tg sample of the 24 hrs 
timepoint and expressed as a fold change of that sample allowing a comparison of replication 
of Ad5ΔΔ against that of wt Ad5tg. 
 
Statistics 
Each experiment was done at least in triplicate. Statistical analysis of data was done using 
Prism Software. The performed tests were one-way ANOVA (nonparametric) column 
analysis including Dunnett‟s post test. This test was used to compare EC50 data of 
combination cytotoxity assays (virus alone vs virus + drug). 
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RESULTS 
Replication of viral mutant Ad5ΔΔ in pancreatic cancer cell lines PANC-1, 
Suit-2 and BxPc-3 
In previous studies, Ad5ΔΔ was shown to be a relatively safe mutant with greatly attenuated 
replication in normal, non-cancerous cells (Dr. Cherubini, personal communication). 
However, its oncolytic potency had only been investigated in one cell line (PT45) that 
supported replication to levels similar to wild type virus. To further determine efficacy in 
pancreatic cancer cells, replication assays were performed in the additional three cell lines, 
PANC-1, Suit-2 and BxPc-3. The corresponding single deleted mutant Ad5Δ19K showed 
promising levels of replication in pancreatic cancer cell lines (PT45 and Suit-2; Leitner et al, 
2009). As the two mutants have the same E1B19K deletion, this data supported the 
expectation that the double-deleted Ad5ΔΔ mutant would also replicate efficiently in cancer 
cells. 
Viral DNA amplification was determined by qPCR in all three cell lines. The PANC-1 
samples were also analysed for viral replication by TCID50 assay. The qPCR data was a 
measure of the amount of viral DNA synthesised, while the TCID50 analysis enabled 
quantification of the number of intact, and therefore infective, viral particles produced in 
pancreatic cells after infection. In the qPCR analysis the viral DNA content of all samples 
were compared to the corresponding content in Ad5tg infected cells at the 24 hrs time point. 
As described in Materials and Methods, the resulting relative levels of viral DNA were 
expressed as fold change of the 24 hrs Ad5tg sample. 
Both qPCR and TCID50 analysis showed that the double deleted mutant Ad5ΔΔ replicates 
efficiently in all pancreatic cancer cell lines, reaching levels comparable to or higher than 
Ad5tg (Fig. 7). When comparing qPCR results, a difference in viral DNA content between 
cell lines was noted. At 72 hrs after infection, the relative content of Ad5ΔΔ and Ad5tg DNA 
in PANC-1 and BxPc-3 cells was almost ten times higher than in Suit-2 (Fig. 7C). These 
differences could be related to variable permissiveness to replication between cell lines, 
however, the same pattern of viral DNA amplification was observed in all cell types. In each 
cell line the viral DNA content increased the most from 24 hrs to 48 hrs after which it 
reached a plateau. This was observed with both qPCR and TCID50 assays. A slight difference 
in qPCR and TCID50 data was seen in PANC-1 samples; according to the TCID50 results the 
wt virus replicated more than Ad5ΔΔ, both at 48 hrs and 72 hrs, indicating that the amount of 
intracellular viral DNA did not correlate to the numbers of infective virions. Despite the 
differences, both analyses showed the same trend in viral replication in the cell line. In 
conclusion, the results of the viral replication assays show that Ad5ΔΔ can replicate 
efficiently in all cell lines tested.  
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Fig.7: Adenoviral mutant Ad5ΔΔ replicates efficiently in pancreatic cancer cell lines 
PANC-1, Suit-2 and BxPc-3.  
Replication of Ad5ΔΔ and Ad5tg in pancreatic cancer cell lines PANC-1 (A+B), Suit-2 (C) and BxPc-3 (D), 
measured by TCID50 (A) and qPCR (B/C/D). A: Replication quantified by TCID50 and expressed as increase in 
PFU/cell over time. All infections were done in duplicates and samples were analysed in duplicates in the 
TCID50 assay. B/C/D: Replication measured by qPCR and displayed as increase in viral DNA content relative to 
the Ad5tg sample 24hrs post infection. A replication defective virus Ad5GFP was added as negative control. All 
infections were done in duplicates and each duplicate was assessed in triplicates qPCR-samples that were 
averaged. Results expressed as average of qPCR data ± SD.  
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Cytotoxic effect of viral mutants and chemotherapeutic drugs on pancreatic 
cancer cell lines PANC-1, Suit-2 and BxPc-3 
The second task of the project was to establish whether Ad5ΔΔ could sensitise cells to the 
cytotoxic actions of Gemcitabine (GEM) and Irinotecan (IRI). Before the cytotoxic potency 
of viral treatment in combination with chemotherapeutics could be evaluated, the effect of 
viruses and drugs on their own had to be investigated. This was done through the generation 
of dose response curves in cell death assays in which pancreatic cancer cells were treated 
with serial dilutions of virus and drug respectively. Three days after infection or treatment, 
the cells were analysed and the EC50 values calculated as described in Materials and 
Methods.  
The viral cytotoxicity data showed that Suit-2 was the least sensitive cell line with average 
EC50 values of 182 ± 44 ppc for Ad5tg, 540 ± 36 for Ad5Δ19K, 993 ± 121 for Ad5ΔΔ and 
2437 ± 603 for ONYX-015 (Fig. 8A). PANC-1 consistently showed the highest levels of 
sensitivity to the viruses with average EC50 values of 34 ± 13 ppc for Ad5tg, 55 ± 9 for 
Ad5Δ19K, 164 ± 4 for Ad5ΔΔ and 445 ± 25 for ONYX-015. In BxPc-3 cells EC50 values 
similar to the ones of PANC-1 cells were observed: 57 ± 19 ppc for Ad5tg, 180 ± 54 for 
Ad5Δ19K, 204 ± 59 for Ad5ΔΔ and 618 ± 120 for ONYX-015. Despite varying levels of 
sensitivity to virally induced cell death, the relationship between the viruses was preserved in 
all cell lines (Fig. 8A). Ad5tg was consistently the most potent virus, followed by, in 
descending order, Ad5Δ19K, Ad5ΔΔ and ONYX-015.  
The drug dose response results showed varying sensitivity to Gemcitabine and Irinotecan in 
the three cell lines (Fig. 8B). With average EC50 values of 14.6 ± 4 nM for Gemcitabine and 
6.7 ± 1.9 μM for Irinotecan, Suit-2 proved to be the most sensitive cell line to drug-induced 
cell death. The corresponding EC50 values in the other cell lines were 10.4 ± 8.8 μM (PANC-
1) and 2.5 ± 1.6 μM (BxPc-3) for Gemcitabine and 44.1 ± 12.4 μM (PANC-1) and 31.4 ± 8.5 
μM (BxPc-3) for Irinotecan. Despite the fact that the experiments were repeated 3-5 times, 
the overall variation between assays is remarkably large, especially in the cells showing 
insensitivity to the drugs.  
The results from the single treatments suggest an inverted correlation between sensitivity to 
viral infection and chemodrugs. PANC-1 cells were the most sensitive to viral treatment but 
the most insensitive to chemodrugs. Suit-2, on the other hand, was the most sensitive cell line 
to drug treatment but showed the highest resistance to the viruses.  By comparing the viral 
replication data (Fig. 7) with the cytotoxicity assays, it became clear that the sensitivity of a 
cell line to viral treatment corresponded well with its permissiveness to viral replication. 
Viral replication was lowest in Suit-2 cells, which also showed the highest resistance to 
virally induced cytotoxicity. Viruses replicated the most in PANC-1 cells, which showed the 
highest levels of sensitivity to viral infection.   
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Fig. 8: Sensitivity to viral mutants and chemotherapeutics in pancreatic cell lines PANC -1, 
Suit-2 and BxPc-3.  
All infections and treatments were done in triplicates and repeated at least twice; data represent average EC50 
values ± SD. A: Single treatment dose-response cytotoxicity assays using wild type Ad5tg and viral mutants 
Ad5Δ19K, Ad5ΔΔ and ONYX-015. B: Dose response assays using serial dilutions of chemotherapeutic drugs 
Gemcitabine and Irinotecan.  
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Combination of viral mutants and chemodrugs in pancreatic cancer cell 
lines PANC-1, Suit-2 and BxPc-3 
Once the dose response relationship of viruses and drugs had been established in each cell 
line, combination treatment cytotoxicity assays using both viral mutants and cytotoxic drugs 
were performed. This was done in order to answer the third question of the project: Would 
the double deleted Ad5ΔΔ retain the ability of its single deleted counterpart Ad5Δ19K to 
sensitise pancreatic cancer cells to chemotherapeutics? Combining viral mutants with 
cytotoxic drugs could be an effective way to increase the potency of the virus and/or the drug. 
If Ad5ΔΔ showed an ability to sensitise pancreatic cancer cells to cytotoxic drugs, 
combination therapies could prove to be a way of optimising the therapeutic effects in future 
clinical settings. By combining viral and drug treatment, the doses of both components can 
potentially be lowered, decreasing side effects.  
Because it is the drug of choice in the treatment of pancreatic cancer, Gemcitabine was the 
drug primarily chosen for the combination studies. However, many pancreatic tumours often 
prove insensitive or resistant to the drug (Akada et al, 2005). We therefore included a second 
drug, Irinotecan, which is also currently used in the treatment of pancreatic cancer, but only 
in combination with Gemcitabine. As described in the introduction, both drugs inhibit DNA 
replication, but target different mechanisms. 
In previous work by Dr. Cherubini, the double deleted mutant Ad5ΔΔ was found to sensitise 
pancreatic cancer cell line PT45 to Gemcitabine, achieving greatly increased levels of cell 
killing (unpublished data). The Ad5Δ19K mutant has also shown ability to significantly 
enhance Gemcitabine-induced cell death in PT45 and Suit-2 cells (Leitner et al, 2009). It was 
therefore tested if the combination of Ad5ΔΔ and chemodrugs could lead to sensitisation in a 
broader panel of pancreatic cancer cell lines (PANC-1, Suit-2 and BxPc-3). 
In order to evaluate if sensitisation between two treatments occurs, the level of cell death 
induced by each component alone had to be low, otherwise any effects of the combination 
might have been masked. Drug concentrations inducing levels of 20% and 30% cell death as 
single treatment were used in combination treatment assays. For each experiment, the 
chemodrug doses were chosen from the single treatment dose response curves generated for 
both drugs in that particular cell line. The chosen doses for combination treatments never 
induced more than 35% cell death in any of the cell lines tested.  
Combination of viral mutants and Gemcitabine shows dose-dependent 
antagonism in PANC-1 cells  
From the single treatment dose response experiments performed in PANC-1 cells, it was 
concluded that the cells were highly insensitive to Gemcitabine with average EC50 values of 
10.4 μM (± 8.8 μM) (Fig. 8B). The Gemcitabine concentrations for the initial combination 
treatment assay were chosen from the dose response data to 100nM and 200nM. The two 
doses induced as single treatments only 24% and 35% cell death respectively. In combination 
with Ad5tg and viral mutant Ad5Δ19K, high levels of antagonism was observed, with over a 
150-fold increase in EC50 values for Ad5tg and almost a 100-fold in Ad5Δ19K (Fig. 9). The 
experiment was repeated with decreasing doses of Gemcitabine; in total seven different 
concentrations were tested, ranging from 5nM to 200nM. No cell death was observed by drug 
alone at doses < 100nM. The double deleted mutant Ad5ΔΔ was tested with a smaller range 
of drug doses (5nM, 10nM and 100nM) and showed dose dependent antagonism in a similar 
fashion to Ad5Δ19K (Fig. 9). Because both mutants showed the same behaviour in PANC-1 
cells, the full range of drug concentrations was only tested on Ad5Δ19K and Ad5tg. 
21 
 
Interestingly, the level of antagonism when Ad5tg was used in the combination treatment was 
consistently higher than with both deletion mutants. 
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Fig. 9: Combination treatments with Gemcitabine (GEM) in PANC-1 cells. 
Cytotoxicity assays performed with serial dilutions of viral mutants in combination with fixed, suboptimal doses 
of drug. Cells were infected and treated simultaneously with virus and drug 24 hrs after seeding (5000 
cells/well). The analysis was performed 72 hrs after infection. Drug doses ranged from 5nM to 200nM, drug 
induced cell death never exceeded 35%. Infections were done in triplicates; for each combination one 
experiment was performed. Results are displayed as percentages of cell death induced by the virus alone. Values 
higher than that of single treatment imply antagonism; lower values suggest sensitisation to the drug by the 
virus.  
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No effect of combining viral mutants with Irinotecan in PANC-1 cells 
Following the observation that cytotoxicity was decreased when combining Gemcitabine with 
viral therapy, we wanted to see if the antagonistic effect was present when using Irinotecan. 
Combination treatments with suboptimal doses of Irinotecan and serial dilutions of viral 
mutants were therefore performed. The drug doses were chosen from single treatment dose 
response curves, with the intention to use drug concentrations that produced around 20% and 
30% cell death. 5μM and 10μM were chosen to be the most suitable for combination 
treatment, inducing on average < 25% cell death alone. Repeats were performed for 
experiments with Ad5tg and Ad5ΔΔ but not for Ad5Δ19K. No statistical analysis could 
subsequently be performed on the data for Ad5Δ19K.  
The EC50 values of the combination treatments were on average marginally lower than the 
value of virus alone with all mutants tested, except for Ad5tg combined with 5μM Irinotecan 
(Fig. 10). However, no statistically significant difference could be observed when comparing 
combination treatments with virotherapy (Ad5tg and Ad5ΔΔ) alone. The results suggest that 
combining viruses with Irinotecan neither increases nor counteracts cytotoxicity in PANC-1 
cells. However, additional experiments with improved reproducibility are necessary to clearly 
determine the response to combination treatments using Irinotecan. 
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Fig. 10: Combination treatments with Irinotecan (IRI) in PANC-1 cells.  
Cytotoxicity assays performed with combination of virus and with two fixed, suboptimal doses of drug. Cells 
were infected and treated simultaneously with virus and drug 24 hrs after seeding (5000 cells/well). The analysis 
was performed 72 hrs after infection. Drug induced cell death never exceeded 25%. Infections were done in 
triplicates; combination treatments using Ad5tg and Ad5ΔΔ were performed twice. Results are displayed as 
average percentages of cell death induced by the virus alone ± SD.  
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Viral mutants show sensitisation to Gemcitabine and Irinotecan in Suit -2 cells 
Following the results in kRas independent PANC-1, combination treatment cytotoxicity 
assays were performed on kRas dependent Suit-2 cells with two fixed doses of Gemcitabine 
and Irinotecan (Fig. 11). The drug doses chosen from dose response data were doses of low 
cytotoxic effect; the average percentage of cell death induced by the drug alone were 18% 
and 20% for 5nM and 6nM of Gemcitabine respectively and 10% and 35% for Irinotecan 
1.5μM and 3μM respectively.  
All viruses showed ability to sensitise Suit-2 cells to both Gemcitabine and Irinotecan, 
including the wildtype Ad5tg (Fig. 9). Because none of the chemodrug doses induced 
substantial levels of cell death on their own, the effects of the combinations of viral and drug 
treatment were due to sensitisation. Statistically significant decrease in EC50 values was 
observed in all viruses when combined with Gemcitabine (* p < 0.05); especially when using 
Ad5Δ19K and Ad5ΔΔ. No significant increase in cell death was reached in combination with 
the lowest Irinotecan dose (1.5μM) but with the higher one (3μM). This was only observed 
for Ad5tg, Ad5Δ19K and Ad5ΔΔ but not for ONYX-015. The latter achieved no sensitisation 
of Suit-2 cells to Irinotecan. Overall, the sensitisation effect appeared to be dose dependent, 
with increasing drug concentrations leading to a proportional decrease in EC50 values, and 
Ad5∆∆ in combination with both chemodrugs achieved the highest levels of sensitisation. 
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Fig. 11: Viral mutants show sensitisation to chemotherapy in Suit -2 cells.  
Combination treatment cytotoxicity assays using serial dilutions of virus and fixed, suboptimal concentrations of 
Gemcitabine (GEM) and Irinotecan (IRI). Cells were infected 24 hrs after seeding (5000 cells/well) and plates 
were read 72hrs after infection. Infections and drug treatments were done simultaneously. All infections were 
done in triplicates and the experiment repeated up to three times for all mutants. Data represent EC50 averages ± 
SD; * p < 0.05. 
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Antagonistic effect of combining viral mutants with Gemcitabine in BxPc-3 cells  
Once the effect of combination therapy had been established in the kRas mutated cell lines 
PANC-1 and Suit-2, a pancreatic cancer cell line with the kRas wild type was tested in 
similar combination assays. Combinations with Gemcitabine and viral mutants were tested 
first. After testing several doses of Gemcitabine, two suboptimal drug doses were chosen 
from single treatment dose response curves: Gemcitabine 20nM and 30nM producing on 
average 6% and 10% cell death respectively as single treatments.  
In the combination treatment assay of BxPc-3 cells a slight tendency towards antagonism 
between Gemcitabine and the viral mutants was observed (Fig. 12).  Combination with the 
higher drug dose (30nM) showed significant increases in EC50 values of all viruses (* p < 
0.05). Similar to the results in PANC-1, Ad5tg showed the most prominent antagonistic effect 
in combination with the drug, whereas Ad5∆∆ and Ad5∆19k induced the smallest increase in 
EC50 values. 
No effect of combining viral mutants with Irinotecan in BxPc-3 cells 
In view of the fact that no sensitisation was observed in combination treatments of BxPc-3 
cells with Gemcitabine, but rather antagonism, cytotoxicity assays were repeated using 
Irinotecan. From dose response data drug doses of low toxicity were chosen to 6μM and 
8μM. As single treatments these concentrations induced on average 16% and 20% cell death 
respectively.  
All viral mutants, except ONYX-015, showed a trend towards sensitisation when combined 
with Irinotecan (Fig. 12). However, no statistically significance of the decrease in EC50 
values could be established. The results of the Irinotecan combination assay as well as the 
experiments performed with Gemcitabine, show similar behaviour in BxPc-3 cells as seen in 
PANC-1 cells.  
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Fig. 12: Combination treatments with viral mutants and chemodrugs Gemcitabine (GEM) 
and Irinotecan (IRI) in BxPc-3 cells.  
Average EC50 values of the combination assays expressed as percentage of cell death induced by virus alone. 
All infections were done in triplicates and repeated 2-5 times. Data represent average EC50 values ± SD, * p < 
0.05. Viral mutants show antagonism when combined with Gemcitabine in BxPc-3 cells; no statistically 
significant effect was detected in combination assays using Irinotecan. 
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DISCUSSION 
From the results of this project it was concluded that Ad5ΔΔ replicates efficiently in 
pancreatic cancer cells and that it has the potential to sensitise some cells to chemotherapy. 
However, sensitisation to Gemcitabine or Irinotecan seemed only possible in cell lines that 
already possessed some sensitivity to the drugs. Cells like PANC-1, and to a certain degree 
BxPc-3, that were insensitive to cytotoxic chemicals could not be sensitised by any of the 
viral mutants tested. Instead, dose dependent antagonism was observed in these cells. In cells 
that could be sensitised, i.e. Suit-2, Ad5ΔΔ produced the highest level of sensitisation 
together with Ad5∆19K. However, in drug resistant cell lines, Ad5ΔΔ induced the lowest 
level of antagonism.  True sensitisation to Irinotecan as well as Gemcitabine was only 
achieved in Suit-2 cells when combined with the action of Ad5ΔΔ. In the other two cell lines, 
combination with Irinotecan only produced a trend towards sensitisation but no statistically 
significant change to the virus alone. Gemcitabine, however, showed significant antagonism 
to the virotherapy. These two findings should be taken into account in future work; before 
Ad5ΔΔ can be used in combination with chemotherapy in clinical trials, more research has to 
be done to explore and elucidate the properties of the cancer cells potentially responsible for 
antagonism when combined with viral therapy.  
One difficulty with the combination treatment cytotoxicity assays, especially in Suit-2 and 
BxPc-3, was to choose doses of low cytotoxicity from the dose response curves. The curves 
had in general a very steep incline and an uneven distribution of values with the majority 
around 100% and 0% cell death. This left very few data points in the middle range from 
which the doses generally were chosen. In this area of the dose response curve, marginal 
increases of the drug doses resulted in large changes in cell death observed. In the first MTS 
assay performed in BxPc-3 the dose response curve indicated that doses of around 50nM and 
150nM would result in only 20%-30% cell death. When the combination treatment was 
performed using doses of 55nM and 150nM, the cell death by drug alone exceeded 50% and 
70% respectively and the data could not be used. It is unclear what causes this behaviour in 
the cells. It may be due to changes in metabolism or environmental factors. It may also be 
due to differences in distributing the drug to the cells in single and combination treatments.  
In the data from the viral replication assays, some discrepancy between the PANC-1 TCID50 
and qPCR results was noticed. According to the qPCR data, replication of Ad5∆∆ exceeded 
that of the wt control whereas the TCID50 results showed the opposite. A possible explanation 
for this phenomenon may be weakening of the virus due to repeated freeze-thawing during 
the TCID50 assay. The process of freeze-thawing, done in order to release intracellular viral 
particles, constitutes a physical stress to the virus and can impair its infectivity (Dr. D. Öberg, 
personal communication). As the first TCID50 assay using PANC-1 samples had to be 
performed twice, the repeated stress to the virus may have inhibited the viral infectivity. It is 
however remarkable that no decrease was seen in the effect of the wt control. This may 
suggest that Ad5∆∆ is more sensitive to physical stress than its wt counterpart, potentially 
due to its double deletions. 
One possible explanation for the antagonism to Gemcitabine is its inhibition of viral 
replication. Gemcitabine is a nucleotide analogue, blocking DNA-synthesis through 
premature chain termination. It is plausible that Gemcitabine is incorporated into the viral 
genome, inhibiting further replication of virus. Once the viral replication is blocked, the 
cytotoxic ability of the virus is lost as it relies on lysis by progeny virions to kill the cell. In 
accordance with this theory, higher levels of replication would also lead to higher levels of 
antagonism, something which was observed in PANC-1 cells. The suggestion that 
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Gemcitabine inhibits viral replication is supported by the work of Leitner et al (2009) and 
Raki et al (2005). Both groups showed Gemcitabine-induced delay of adenoviral replication 
in pancreatic and ovarian cancer cells respectively. Surprisingly, in both studies, the viral 
mutants retained ability to sensitise cells despite decrease in replication. To investigate if 
Gemcitabine has an inhibiting effect on viral replication in the pancreatic cancer cell lines 
used in this project, the replication studies need to be repeated in the presence of the drug.  
It can prove harder to explain what property of the cell lines may contribute to the observed 
antagonism between chemotherapy and virotherapy. No pattern connected to kRas status of 
the cells was observed. As Gemcitabine is converted to an active metabolite by cellular 
kinases, differences in metabolic activity and enzyme systems between the cell lines could 
potentially explain the variation in drug sensitivity. Further studies analysing the pathways 
responsible for metabolism of Gemcitabine could be undertaken to investigate the matter.  
In previous work on NHBE cells, Dr. Cherubini (manuscript in preparation) found that the 
Ad5∆∆ was not cytotoxic to non-cancerous cells and could not replicate in normal cells.  The 
data from this work in combination with previous work on PT45 cells (Leitner et al, 2009; 
Dr. Cherubini, personal communication) also suggest that the viral mutant is sufficiently 
cytotoxic to pancreatic cancer cells. It would nonetheless be beneficial, in future studies, to 
include additional pancreatic cancer cells lines with other mutations. The cell lines used in 
this study and previous work within the lab have, according to Akada et al (2005), been 
classified as sensitive (PT45, Suit-2) and intermediate sensitive (PANC-1, BxPc-3).  It would 
be interesting to include a resistant cell line in future work with Ad5∆∆. By screening cells of 
all categories of drug sensitivity, more detailed information can be gathered about the 
behaviour of the virus in different cells. Through increased knowledge, the experimental 
setting can be tailored to resemble a clinical situation better.   
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